L. Zhang

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial

Luis Paz‐Ares, E.H. Tan, Kenneth J. O’Byrne et al. · Annals of Oncology · 2017 · 512 citations · Full text

LBA3 Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC): CheckMate 227 - part 2 final analysis

Luis Paz‐Ares, Tudor–Eliade Ciuleanu, Xiaolu Yu et al. · Annals of Oncology · 2019 · 47 citations

Lba3 Nivolumab, Medicine, Part 2 +8

The impact of sharing results of a randomized breast cancer clinical trial with study participants

Ann H. Partridge, Antonio C. Wolff, P. Kelly Marcom et al. · Breast Cancer Research and Treatment · 2008 · 42 citations

Study Participants, Health Policy, Cancer Screening +10

Monotherapy Administration of Sorafenib in Patients with Non-Small Cell Lung Cancer: Phase III, Randomized, Double-Blind, Placebo-Controlled Mission Trial

Luis Paz‐Ares, Vera Hirsh, L. Zhang et al. · Annals of Oncology · 2012 · 24 citations

LBA2_PR Afatinib (A) vs gefitinib (G) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations: results of the global, randomized, open-label, Phase IIb trial LUX-Lung 7 (LL7)

K. Park, E.H. Tan, L. Zhang et al. · Annals of Oncology · 2015 · 16 citations · Full text

Medicine, Lba2_pr Afatinib, Pathology +8